Innospec IOSP Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares at other companies

ZymeworksZYME

9.9K—

PureCycle Technologies, Inc.PCT

54K+125%

Proto LabsPRLB

14.7K+949%

Healthcare Services GroupHCSG

0—

CalixCALX

1.1M+35.9%

SPS CommerceSPSC

3.1K-31.1%

Other financials

Income statement

See full

Revenue$453.2M+2.8%

Gross profit$123.5M-1.3%

Operating income$36.5M-14.1%

Net income$30.4M-7.3%

EPS (diluted)$1.22-6.9%

Balance sheet

See full

Cash & equivalents$289.1M-3.6%

Total debt$50.6M+14.0%

Total equity$1.3B+6.7%

Total assets$1.8B+2.5%

Cash flow

See full

Operating cash flow$17.6M-37.8%

CapEx$8.9M+6.0%

Free cash flow$8.7M-56.3%

Valuation

See full

Market cap$2.05B-23.6%

Profitability

See full

Gross margin27.4%-1.3pp

Operating margin6.9%-2.6pp

Net margin6.4%—

FCF margin4.5%-1.1pp

Returns & leverage

See full

Return on equity8.8%—

Debt / equity0×0.0×

Current ratio3×+0.3×

Where this comes from

Reported directly by Innospec in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares.

The official record: Innospec’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innospec's share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, number of shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Innospec's share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, number of shares?: Innospec (IOSP) reported share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, number of shares of 0 in Q1 2026.